NEPH

Business Context and Reporting Period

Company: Nephros, Inc.
Filing Type: Form 10-Q (Quarterly Report)
Period Ended: June 30, 2009
Business Overview: Nephros develops hemodiafiltration (HDF) products for End Stage Renal Disease (ESRD) and water filtration systems (Dual Stage Ultrafilter or DSU). The company is a smaller reporting company and was delisted from the American Stock Exchange (AMEX) in January 2009, trading subsequently on the OTC Bulletin Board.

Key Financial Metrics

Note: The filing does not provide specific long-term debt figures; interest expense was minimal ($2,000 for the six months ended June 30, 2009), primarily related to insurance financing.

Material Changes vs. Prior Period

• Revenue Growth: Revenues increased 81% year-over-year to $1.158 million. This was driven by $565,000 in revenue from the U.S. Naval Research contract (up from $53,000) and $91,000 from U.S. DSU sales (new product line). European MD filter sales decreased by approximately $85,000 due to production delays.
• Expense Reduction: Operating expenses decreased significantly. Research and Development (R&D) dropped 92% to $150,000, primarily due to the absence of clinical trials in the current period compared to the prior year. Selling, General, and Administrative (SG&A) expenses fell 45% to $1.417 million, driven by reduced headcount, legal fees, and recruiting costs.
• Improved Loss Position: Net loss narrowed by approximately $2.9 million to $1.148 million, reflecting both revenue growth and substantial cost-cutting measures.
• Liquidity: Cash and cash equivalents declined from $2.306 million at year-end 2008 to $890,000 at June 30, 2009, a decrease of $1.416 million.

Outlook, Risks, and Unusual Items

• Going Concern: The filing explicitly states that recurring losses and negative cash flows raise substantial doubt about the company's ability to continue as a going concern. Management projects a need for additional funding before the end of 2010.
• Recent Financing: On July 24, 2009 (subsequent to the period end), the company raised $1.251 million through a private placement of common stock and warrants.
• Regulatory Milestones: The company received FDA approval on July 1, 2009, for its DSU water filtration system for use in hemodialysis procedures. It is also pursuing an additional $2 million appropriation from the U.S. Department of Defense for water filtration development.
• Legal Contingencies:
  • A former U.S. employee filed a claim for breach of contract and fraud; the company has accrued $10,000 (insurance deductible).
  • A former French employee claims back wages of approximately $42,000; the company disputes liability based on a separation agreement.
  • A third party claims damages regarding a cancelled 2008 Auction Rate Securities transaction; no accrual has been recorded as the company denies liability.
• Unusual Items: Other income included approximately $182,000 in New York State Qualified Emerging Technology Company (QETC) tax refunds for the six months ended June 30, 2009.

Investor Verification Checklist

• Cash Runway: Verify the sufficiency of the $890,000 cash balance against current burn rates and the timeline for the required additional funding before end of 2010.
• Revenue Concentration: Assess the risk associated with customer concentration; two customers accounted for 90% of sales in the first six months of 2009 (41% and 49%).
• European Operations: Confirm the status of production delays with the contract manufacturer in Europe and the impact on the backlog of orders.
• Legal Exposure: Monitor the outcomes of the pending FINRA arbitration regarding the Auction Rate Securities and the French employment claim.
• Financing Terms: Review the terms of the July 2009 private placement and any potential dilution from the exercise of outstanding warrants (including placement agent warrants).